Budiodarone Cardioversion for Rapid AFib-to-Sinus Rhythm Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cardioverting patients with paroxysmal or persistent atrial fibrillation (AFib) involve risky electrical cardioversion procedures that pose significant health and financial burdens, and there is a need for a safer, more cost-effective alternative.
Innovation Solution
Administering a single high dose of budiodarone or a pharmaceutically acceptable salt thereof, such as budiodarone tartrate, to patients with AFib to achieve a plasma concentration of at least 13 ng/ml for at least 6 hours, followed by monitoring to confirm cardioversion back to sinus rhythm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electrical cardioversion is used to restore sinus rhythm, then the patient's AFib can be converted back to normal rhythm, but the patient faces elevated risk of death and complications
Solution Approach 1:
The patent replaces the mechanical/electrical cardioversion system with a pharmacological system. Instead of using electrical shocks to cardiovert AFib, the invention uses a specific combination of medications (Class IC antiarrhythmic agent and Class III antiarrhythmic agent) to achieve cardioversion through chemical mechanisms, thereby eliminating the mechanical stress and associated risks of electrical cardioversion
Solution Approach 2:
The patent introduces pharmacological agents as intermediaries between the AFib condition and the desired sinus rhythm. The Class IC and Class III antiarrhythmic agents act as mediators that modify the electrical properties of the heart tissue, facilitating rhythm conversion without direct electrical intervention, thus reducing harmful effects
2Reliability
If electrical cardioversion is performed, then sinus rhythm can be restored, but significant healthcare costs are incurred
Solution Approach 1:
The patent employs a cost-effective pharmacological approach using oral medications that can be administered without expensive infrastructure. The Class IC and Class III antiarrhythmic agents are administered as oral medications, eliminating the need for expensive electrical cardioversion equipment, specialized facilities, and extensive personnel, thereby significantly reducing healthcare costs
Solution Approach 2:
By substituting the expensive electrical cardioversion system with a pharmacological system, the invention reduces the resource requirements for cardioversion. The medication-based approach eliminates costs associated with electrical equipment, monitoring facilities, and specialized personnel, making cardioversion more economically viable
3Reliability
If electrical cardioversion is used, then AFib can be converted to sinus rhythm, but multiple specialists and resources are required
Solution Approach 1:
The patent replaces the complex electrical cardioversion system with a simpler pharmacological system. Instead of requiring electrical equipment, monitoring devices, and coordinated specialist teams, the invention uses oral medications that can be administered by primary care providers or even patients themselves, dramatically reducing the complexity of resources and personnel needed
Solution Approach 2:
The patent enables a form of self-service cardioversion where patients can potentially administer the medication themselves or with minimal medical supervision. The oral antiarrhythmic combination can be taken at home without requiring the complex infrastructure and specialized personnel needed for electrical cardioversion, empowering patients to take control of their own rhythm conversion
Data Source
AI summary
Disclosed are cardioversion methods for patients with either paroxysmal or persistent AFib which methods use budiodarone or a pharmaceutical composition comprising budiodarone.